Brooks Laboratories Limited share price

Brooks Laboratories Limited operates as a pharmaceutical manufacturer in India and internationally. It operates in two segments, Manufacturing and Trading. The company offers liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; and B-Lactam and cephalosporin tablets, dry powder syrups, and injections. It is also involved in loan-licensing business relating to pharmaceutical products, ingredients, and intermediaries; and trading in pharmaceutical products, ingredients, and intermediaries. In addition, the company offers oncology products and hormonal injections; and formulations for therapeutic areas comprising antibiotic, p…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: BROOKSISIN INE650L01011

16 Oct 2026, 3:29 PM IST₹67.57▼ 2.85 (4.05%)

Market Cap₹ 199 Cr.
Current Price₹ 67.57
High / Low₹ 125 / 36
Stock P/E15.0
Book Value₹ 42
Dividend Yield0.00 %
ROCE20.0 %
ROE22.30 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ 4.49
Price / Book1.62
OPM6.4 %
Debt / Equity0.07
Sales growth (5Y)2.1 %
Profit growth (5Y)—
Promoter holding54.8 %
EV / EBITDA33.6
Beta1.15
All-time high₹ 199

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
BROOKS	+10.73%	-3.18%	-2.89%	-15.69%	-44.93%	-15.89%	-12.87%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Brooks Laboratories Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹199 crore.
It trades at 15.0 times its last 12 months' earnings and 1.6 times book value.
Revenue grew 2.1% a year over the last 5 years.
Return on equity was 22.3% and return on capital employed 20.0% in the latest year.
Debt was 0.07 times shareholders' equity.
The share price is 46.0% below its 52-week high and down 44.9% over one year.
Promoters and insiders hold about 54.8%; institutions about 9.9%.

Pros

Company is almost debt-free (debt is 0.07 times equity).
Institutional (FII + DII) holding has risen by 7.9 points over 3 years.

Cons

Return on equity has been low: -6.0% on average over the last 3 years.
Sales growth has been slow: 2.1% a year over the last 5 years.
Latest quarter (Jun 2026): profit fell 119% from a year ago.
Promoter holding has fallen by 10.97 points over 3 years, to 52.62%.
The company has not paid a dividend recently.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Brooks Laboratories Limited

Employees: 347
Head office: Mumbai

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Brooks Laboratories	67.57	15.0	199	0.00	-2	-118.64	23	-10.00	20.0	22.3	1.62	6.4	0.07	54.84	86	2.1
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,835	54.57	9.1	27.1	18.39	25.0	1.79	63.18	13,753	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	568	35.00	4,031	30.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 32 Co.	1,712.85	34.3	38,069	0.34	679	8.79	5,956	18.81	16.4	16.9	4.96	18.5	0.21	54.82	20,499	13.5

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	16	24	22	18	18	21	21	23	26	23	17	20	23
YOY Sales Growth %	-8.30%	34.48%	42.10%	40.49%	14.20%	-14.49%	-5.66%	31.57%	42.26%	12.79%	-19.25%	-13.33%	-10.00%
	16	23	21	17	18	19	19	22	22	21	16	20	21
Material Cost %	70%	72%	71%	72%	69%	63%	62%	68%	62%	58%	54%	61%	55%
Employee Cost %	18%	11%	13%	13%	17%	15%	16%	15%	14%	17%	22%	19%	18%
Other Expenses %	12%	10%	11%	13%	13%	14%	14%	11%	11%	14%	19%	16%	18%
Operating Profit	0	2	1	0	0	2	2	2	3	3	1	1	2
OPM %	0%	7%	5%	2%	2%	7%	8%	7%	12%	11%	4%	3%	8%
Other Income	0	0	0	1	0	0	0	1	0	0	0	0	0
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0
Profit before tax	-1	1	1	0	-0	1	1	2	3	2	0	1	1
			4%					12%
Current tax			0					0
	-4	-2	-4	-10	-2	-4	-2	-1	10	8	5	2	-2
Profit from associates	-4	-3	-4	-10	-2	-5	-3	-3	7	6	5	1	-3
Profit to shareholders	-4				-2	-4					5	1	-2
YOY Profit Growth %													-118.64%
EPS in Rs	-1.75	-0.64	-1.51	-3.77	-0.94	-1.51	-0.82	-0.54	3.25	2.71	1.87	0.52	-0.61
Raw filing

₹ Cr	Mar 2023	Jun 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	13	16	22	18	18	21	21	23	26	23	17	20	23
YOY Sales Growth %		5.09%	81.18%	40.49%	14.20%		-5.66%	31.57%	42.26%	12.79%	-19.25%	-13.33%	-10.00%
	13	16	21	17	18	19	19	22	22	21	16	20	21
Material Cost %	65%	70%	71%	72%	69%	63%	62%	68%	62%	58%	54%	61%	55%
Employee Cost %	18%	18%	13%	13%	17%	15%	16%	15%	14%	17%	22%	19%	18%
Other Expenses %	18%	12%	11%	13%	13%	14%	14%	11%	11%	14%	19%	16%	18%
Operating Profit	-0	0	1	0	0	2	2	2	3	3	1	1	2
OPM %	-1%	0%	5%	2%	2%	7%	8%	7%	12%	11%	4%	3%	8%
Other Income	0	0	0	1	0	0	0	1	0	0	0	0	0
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0
Profit before tax	-1	-1	1	0	-0	1	1	2	3	2	0	1	1
			4%					11%
Current tax			0					0
	-1	-1	1	0	-0	1	1	1	3	2	0	1	1
YOY Profit Growth %							62.14%	352.31%		134.10%	-67.67%	-55.24%	-46.48%
EPS in Rs	0.29	-0.22	0.23	0.10	-0.08	0.36	0.36	0.51	0.90	0.76	0.10	0.21	0.48
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	77	91	63	79	83	86	83
YOY Sales Growth %		17.90%	-30.60%	25.76%	3.86%	3.85%
	77	105	90	76	78	79	77
Material Cost %	62%	69%	80%	71%	65%	60%	57%
Employee Cost %	19%	21%	27%	13%	16%	18%	19%
Other Expenses %	19%	26%	34%	11%	13%	15%	17%
Operating Profit	1	-14	-26	3	5	7	6
OPM %	1%	-16%	-42%	4%	6%	8%	7%
	1	1	0	1	1	1	1
Exceptional items			-0
Interest	3	3	2	1	1	1	1
Depreciation	7	7	7	2	2	2	2
Profit before tax	-9	-24	-36	2	3	6	5
				2%	5%
Current tax	7			0	0
Deferred tax	3	-5	-7
	-19	-19	-32	-20	-10	25	13
Profit from associates	-0		-3	-21	-13	19	9
Minority share		-3	-10
Profit to shareholders	-19	-16	-21			25
EPS in Rs	6.31	-7.82	-12.57	-7.67	-3.72	8.35	4.49

Compounded Sales Growth

5 Years:: 2%
3 Years:: 11%
TTM:: -8%

Compounded Profit Growth

TTM:: 550%

Stock Price CAGR

5 Years:: -13%
3 Years:: -16%
1 Year:: -45%

Return on Equity

4 Years:: -12%
Last Year:: 22%

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	57	55	70	77	56	79	83	86	83
YOY Sales Growth %		-3.29%	26.64%	10.44%	-27.84%	43.12%	3.86%	3.85%
	66	63	74	75	61	76	78	79	77
Material Cost %	69%	72%	67%	64%	73%	71%	65%	60%	57%
Employee Cost %	21%	22%	19%	17%	21%	13%	16%	18%	19%
Other Expenses %	26%	21%	19%	17%	17%	11%	13%	15%	17%
Operating Profit	-9	-8	-4	2	-6	3	5	7	6
OPM %	-16%	-15%	-6%	2%	-10%	4%	6%	8%	7%
Other Income	0	3	0	1	0	1	1	1	1
Interest	2	3	3	1	1	1	1	1	1
Depreciation	6	6	7	1	2	2	2	2	2
Profit before tax	-18	-15	-14	1	-8	2	3	6	5
						2%	5%
Current tax						0	0
Deferred tax	-4	-0	11
	-14	-15	-24	1	-8	2	3	6	5
YOY Profit Growth %					-1,329.91%		99.67%	90.19%
EPS in Rs	-5.69	-6.13	-13.84	0.27	3.32	0.58	1.14	1.97	1.55

Compounded Sales Growth

5 Years:: 4%
3 Years:: 16%
TTM:: -8%

Compounded Profit Growth

TTM:: -23%

Stock Price CAGR

5 Years:: -13%
3 Years:: -16%
1 Year:: -45%

Return on Equity

4 Years:: -12%
Last Year:: 22%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	25	26	29	29
Reserves	49	39	69	93
	7	6	8	9
Long term borrowings			0	1
Short term borrowings	6	5	6	6
	29	19	18	17
Trade payables	23	15	14	11
Current liabilities	33	23	23	22
Total Liabilities	110	90	124	148
	15	14	14	16
Gross block	22	23	25	27
Accumulated depreciation	7	9	10	11
Goodwill & intangibles	0	0	0
CWIP			0	2
	95	77	109	130
Inventories	11	10	9	11
Trade receivables	13	16	20	16
Cash & equivalents	0	0	0	7
Current assets	28	31	34	37
Total Assets	110	90	124	148

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-14	-10	3	9
Profit for the year	-21	-20	-10	25
Working capital changes	11	-13	-3	2
Direct taxes paid	-0	0	1	0
	0	0	-45	-3
Fixed assets purchased	-0	-0	-1	-4
Fixed assets sold			0	0
Investments purchased			-1
Investments sold		1		0
	11	10	42	0
Interest paid	-2	-1	-1	-1
Net Cash Flow	-3	0	-0	7
Free Cash Flow	-15	-10	2	6

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	-28.3%	-28.1%	-12.2%	22.3%
ROCE	—	-47.6%	-28.0%	-8.9%	20.0%
Operating margin	—	-53.7%	1.8%	7.9%	6.4%
Net margin	—	-33.4%	-24.8%	-12.1%	28.8%
Debt / equity	—	0.09	0.09	0.08	0.07
Current ratio	—	0.84	1.35	1.48	1.72
Debtor days	—	75	75	89	69
Inventory days	—	67	57	57	71
Days payable	—	139	92	84	73
Cash conversion cycle	—	3	40	62	67
Working capital days	—	-32	37	49	67

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 52.62%
DIIs 10.38%
Public 37.00%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	63.59%	63.59%	63.59%	63.59%	63.59%	59.06%	52.62%	52.62%	52.62%	52.62%	52.62%	52.62%
					0.02%	0.01%	0.05%		0.01%	0.09%	0.17%
Foreign portfolio investors (Cat. I)					0.02%	0.01%	0.04%		0.01%	0.09%	0.17%
Foreign portfolio investors (Cat. II)							0.01%
	2.46%	3.86%	3.86%	3.86%	3.86%	3.86%	10.38%	10.38%	10.38%	10.38%	10.38%	10.38%
Mutual funds	2.46%	3.86%	3.86%	3.86%	3.86%	3.86%	9.90%	9.90%	9.90%	9.90%	9.90%	9.90%
	33.94%	32.55%	32.55%	32.55%	32.53%	37.08%	36.95%	37.00%	37.00%	36.91%	36.84%	37.00%
Retail (up to ₹2 lakh)	17.81%	16.66%	18.10%	19.26%	20.23%	20.21%	18.04%	17.70%	17.09%	17.09%	17.31%	18.35%
HNIs (above ₹2 lakh)	9.07%	8.56%	7.44%	6.31%	8.31%	12.13%	13.82%	14.31%	14.61%	14.75%	14.25%	12.38%
NRIs	0.76%	0.85%	0.87%	0.89%	0.87%	0.83%	0.65%	0.48%	0.48%	0.43%	0.36%	0.92%
Bodies corporate	4.28%	4.47%	4.37%	4.17%	2.01%	2.67%	3.32%	3.16%	2.84%	2.46%	2.94%	3.29%
No. of Shareholders	10,686	10,028	11,432	11,543	11,282	10,521	10,537	10,317	10,078	10,532	10,741	11,161

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Brooks Laboratories

Holder (above 1%)	Stake
quant Business Cycle FundMutual fund	9.90%

As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 9.90% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

None filed recently.

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 1 Jan 1970
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Brooks Laboratories Limited

What is the share price of Brooks Laboratories Limited today?

Brooks Laboratories Limited (BROOKS) last traded at ₹67.57 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Brooks Laboratories Limited?

About ₹199 crore at the latest price.

What is the P/E ratio of Brooks Laboratories Limited?

About 15.0 times its earnings over the last 12 months.

Is Brooks Laboratories Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Brooks Laboratories Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Brooks Laboratories Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Brooks Laboratories Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Brooks Laboratories

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Brooks Laboratories Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next